Advertisement

Topics

Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors

08:00 EDT 12 Jul 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
-Trial to Inform Broader Development Program Strategy- -Trial is Enrolling Patients with Colorectal, Non-Small Cell Lung, Pancreatic or Head and Neck Cancers- Seattle Genetics, Inc. (Nasdaq:SGEN) to...

Other Sources for this Article

Seattle Genetics, Inc.
Media:
Monique Greer, (425) 527-4641
mgreer@seagen.com
or
Investors:
Peggy Pinkston, (425) 527-4160
ppinkston@seagen.com

NEXT ARTICLE

More From BioPortfolio on "Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pulmonary
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza,  Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...